Fosun Pharmaceutical publishes the global offering results

Source: Shanghai Fosun Pharmaceutical (Group) Co., Ltd has a final price of HK $11.8 per share on October 30, 2012 [Hong Kong news, October 29, 2012] Shanghai Fosun Pharmaceutical (Group), China's leading pharmaceutical and health enterprise Limited liability company ("Fosun Pharma" or "the company", together with its subsidiary "the group") today announced the results of the international placement and Hong Kong public offering, with a price of HK $11.8 per share Fosun Pharmaceutical's shares will be traded on the main board of the stock exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") on Tuesday, October 30, 2012 The stock code is 2196, with 500 shares in each hand As the second largest pharmaceutical company in the world since 2012, Fosun Pharmaceutical's H-share listing has attracted many representative diversified international institutional investors, including sovereign funds, international long-term funds, insurance funds and private banking customers in Asia and Europe In terms of public offering in Hong Kong, Fosun Pharmaceutical has more than twice the coverage, which is one of the most enthusiastic new shares this year Before the exercise of the over allotment rights, after deducting the relevant underwriting commissions and expenses, the net proceeds from the global offering were about HK $3764.4 million, of which about 48% was used for the acquisition and merger of the group in the fields of pharmaceuticals, pharmaceutical distribution and retail, medical services and diagnostic products and medical devices As one of the fastest growing markets in the world, we believe that in the next 5-10 years, China's pharmaceutical market will become the second largest market in the world At present, the top 10 pharmaceutical companies in the United States occupy 77.8% of the market share of the U.S market, while the top 100 pharmaceutical companies in China only occupy 40% of the market share of the Chinese pharmaceutical market, and the top 10 pharmaceutical companies occupy less than 16% We believe that the market share of China's leading pharmaceutical companies has unlimited potential for growth According to IMS Health incorporated, Fosun Pharma is one of the top five local pharmaceutical companies in China based on its pharmaceutical segment revenue in 2011 Since A-share was listed in 1998 for 14 years, its net profit has increased 21 times, and its compound annual growth rate has reached 26.72% After being selected into Shanghai 180 index, Shanghai 300 index, Shanghai dividend index and Shanghai corporate governance index, Fosun Pharmaceutical also successfully selected into Shanghai private enterprise 50 index and Shanghai social responsibility index As a leading pharmaceutical and health enterprise in China, the group's business strategy covers many important links in the value chain of the pharmaceutical and health industry, with strong R & D capabilities and a strong research product line focusing on biopharmaceuticals It is also one of the pioneers in China's leading pharmaceutical and health enterprises in the high-end, specialized and comprehensive medical service industries Fosun Pharmaceutical currently owns 32.1% equity of Sinopharm, which is its second largest beneficial shareholder At present, Sinopharm has become the largest drug distributor in China, with sales network covering more than half of hospitals in China Fosun medicine has been maintaining a rapid performance growth, the overall income compound annual growth rate reached 29.3% from 2009 to 2011, and the compound annual growth rate of gross profit reached 40.3% It is expected that the proportion of shareholders of the company in the comprehensive profit forecast for the year ended December 31, 2012 will not be less than RMB 1.49 billion, an increase of 27.8% over the same period of last year, and its development in China can be said to have unlimited potential -Continued - UBS Hong Kong Branch ("UBS"), China International Finance Hong Kong Securities Limited ("CICC"), JPMorgan securities (Asia Pacific) Limited ("JPMorgan") and Deutsche Bank Hong Kong Branch ("Deutsche Bank") are the joint global coordinators of this listing UBS Securities Hong Kong Limited, CICC, J.P Morgan Securities (Far East) Limited and Deutsche Bank are the co sponsors of the listing plan UBS, CICC, JPMorgan and Deutsche Bank are the joint bookrunners and joint lead managers of the Hong Kong public offering UBS, CICC, J.P Morgan Securities PLC, Deutsche Bank, ABC International Securities Co., Ltd and Haitong International Securities Co., Ltd are the joint bookrunners and joint lead managers of the international offering of the listing plan Mr Chen Qiyu, executive director and chairman of Fosun Pharmaceutical, said: "we are very honored that investors from all walks of life have been giving strong support to the company's H-share listing on the Hong Kong stock exchange This successful listing is an important milestone for the company to move towards the international capital market At present, with the company's leading position in various business areas, we continue to invest in innovative research and development, and constantly increase the market share of pharmaceutical and other business segments in the Chinese market, striving to consolidate and further enhance our leading position in the industry Fosun Pharma is committed to accelerating the implementation of its international strategy by acquiring overseas pharmaceutical enterprises with advantages or huge potential in China and pharmaceutical enterprises with unique product lines, R & D capabilities and sales networks in the international market With the rapid growth of China's pharmaceutical market, Fosun Pharmaceutical is ready to seize the opportunity in the current potential market and bring the greatest return to investors We are full of confidence in the rapid development of the company's business "